Pharma companies routinely update analysts, but a Securities and Exchange Commission (SEC) punishment for tiny TherapeuticsMD might offer a lesson—or reminder—for the rest of the industry.
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved Imvexxy (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (